The γ-secretase modulator, BMS-932481, modulates Aβ peptides in the plasma and cerebrospinal fluid of healthy volunteerss

Journal of Pharmacology and Experimental Therapeutics

Volumn 358, Issue 1, 2016, Pages 138-150

  Soares, Holly D ^a   Gasior, Maciej ^b   Toyn, Jeremy H ^a   Wang, Jun Sheng ^c   Hong, Quan ^d   Berisha, Flora ^e   Furlong, Michael T ^f   Raybon, Joseph ^a   Lentz, Kimberley A ^a   Sweeney, Francis ^g   Zheng, Naiyu ^a   Akinsanya, Billy ^a   Berman, Robert M ^h   Thompson, Lorin A ^a   Olson, Richard E ^a   Morrison, John ^a   Drexler, Dieter M ^a   Macor, John E ^a   Albright, Charlie F ^a   Ahlijanian, Michael K ^a   AbuTarif, Malaz ^a   more..

^a BRISTOL MYERS SQUIBB   (United States)

^b TEVA PHARMACEUTICALS   (Israel)

^c GLAXOSMITHKLINE   (United States)

^d EISAI INC   (United States)

^e KYOWA HAKKO KOGYO CO LTD   (Japan)

^f FORUM Pharmaceuticals   (United States)

^g PFIZER INC   (United States)

^h Biohaven Medical Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN 37; AMYLOID BETA PROTEIN 38; AMYLOID BETA PROTEIN 39; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOLOGICAL MARKER; BMS 932481; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; GLUCURONOSYLTRANSFERASE 1A1; HEMOGLOBIN; PLACEBO; UNCLASSIFIED DRUG; ANILINE DERIVATIVE; BMS-932481; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIMIDINE DERIVATIVE; SECRETASE;

ADULT; ADVERSE OUTCOME; AGED; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME INHIBITION; FEMALE; HEMATOCRIT; HUMAN; HUMAN EXPERIMENT; HYPERBILIRUBINEMIA; LEUKOCYTE COUNT; LIVER TOXICITY; LYMPHOCYTE COUNT; MALE; MAXIMUM PLASMA CONCENTRATION; NEUTROPHIL COUNT; NORMAL HUMAN; OUTCOME ASSESSMENT; PH MEASUREMENT; PHARMACOGENOMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; ADOLESCENT; ALZHEIMER DISEASE; BLOOD; CEREBROSPINAL FLUID; CHEMISTRY; DOSE RESPONSE; ENZYMOLOGY; LIMIT OF DETECTION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANILINE COMPOUNDS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AREA UNDER CURVE; CHROMATOGRAPHY, LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HEALTHY VOLUNTEERS; HUMANS; LIMIT OF DETECTION; MALE; MASS SPECTROMETRY; MIDDLE AGED; PYRIMIDINES; YOUNG ADULT;

EID: 84976447977     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.116.232256     Document Type: Article

References (47)

1. Alzheimer's Association (2014) 2014 Alzheimer's disease facts and figures. Alzheimers Dement 10:e47-e92.
2. Barber RC (2012) The genetics of Alzheimer's disease. Scientifica (Cairo) 2012:246210.
3. Barten DM, Meredith JE, Jr, Zaczek R, Houston JG, and Albright CF (2006) Gammasecretaseinhibitors for Alzheimer's disease: balancing efficacy and toxicity. Drugs R D 7:87-97.
4. Beher D, Wrigley JD, Owens AP, and Shearman MS (2002) Generation of C-terminally truncated amyloid-beta peptides is dependent on gamma-secretaseactivity. J Neurochem 82:563-575.
5. Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, Prada CM, Kim G, Seekins S, and Yager D, et al. (1996) Familial Alzheimer's diseaselinkedpresenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo. Neuron 17:1005-1013.
6. Borgegard T, Juréus A, Olsson F, Rosqvist S, Sabirsh A, Rotticci D, Paulsen K, Klintenberg R, Yan H, and Waldman M, et al. (2012) First and second generationγ-secretase modulators (GSMs) modulate amyloid-b Aβ peptide productionthrough different mechanisms. J Biol Chem 287:11810-11819.
7. Caldwell JP, Bennett CE, McCracken TM, Mazzola RD, Bara T, Buevich A, Burnett DA, Chu I, Cohen-Williams M, and Josein H, et al. (2010) Iminoheterocycles asgamma-secretase modulators. Bioorg Med Chem Lett 20:5380-5384.
8. Coric V, van Dyck CH, Salloway S, Andreasen N, Brody M, Richter RW, Soininen H, Thein S, Shiovitz T, and Pilcher G, et al. (2012) Safety and tolerability of theγ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimerdisease. Arch Neurol 69:1430-1440.
9. De Strooper B (2003) Aph-1, Pen-2, and Nicastrin with Presenilin generate an activegamma-Secretase complex. Neuron 38:9-12.
10. De Strooper B, Iwatsubo T, and Wolfe MS (2012) Presenilins and γ-secretase:structure, function, and role in Alzheimer disease. Cold Spring Harb Perspect Med2:a006304.
11. del Campo M, Mollenhauer B, Bertolotto A, Engelborghs S, Hampel H, Simonsen AH, Kapaki E, Kruse N, Le Bastard N, and Lehmann S, et al. (2012) Recommendationsto standardize preanalytical confounding factors in Alzheimer's and Parkinson'sdisease cerebrospinal fluid biomarkers: an update. Biomarkers Med 6:419-430.
12. Diczfalusy U, Nylén H, Elander P, and Bertilsson L (2011) 4b-Hydroxycholesterol, anendogenous marker of CYP3A4/5 activity in humans. Br J Clin Pharmacol 71:183-189.
13. Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, He F, SunX, and Thomas RG, et al.; Alzheimer's Disease Cooperative Study Steering Committee;Semagacestat Study Group (2013) A phase 3 trial of semagacestat fortreatment of Alzheimer's disease. N Engl J Med 369:341-350.
14. Dries DR and Yu G (2008) Assembly, maturation, and trafficking of the gammasecretasecomplex in Alzheimer's disease. Curr Alzheimer Res 5:132-146.
15. Fleisher AS, Raman R, Siemers ER, Becerra L, Clark CM, Dean RA, Farlow MR, Galvin JE, Peskind ER, and Quinn JF, et al. (2008) Phase 2 safety trial targetingamyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol 65:1031-1038.
16. Golde TE, Koo EH, Felsenstein KM, Osborne BA, and Miele L (2013) γ-Secretaseinhibitors and modulators. Biochim Biophys Acta 1828:2898-2907.
17. Goodenough AK, Onorato JM, Ouyang Z, Chang S, Rodrigues AD, Kasichayanula S, Huang SP, Turley W, Burrell R, and Bifano M, et al. (2011) Quantification of4-beta-hydroxycholesterol in human plasma using automated sample preparationand LC-ESI-MS/MS analysis. Chem Res Toxicol 24:1575-1585.
18. Haass C and Selkoe DJ (1993) Cellular processing of beta-amyloid precursor proteinand the genesis of amyloid beta-peptide. Cell 75:1039-1042.
19. Ishii K, Ii K, Hasegawa T, Shoji S, Doi A, and Mori H (1997) Increased A beta 42(43)-plaque deposition in early-onset familial Alzheimer's disease brains with thedeletion of exon 9 and the missense point mutation (H163R) in the PS-1 gene. Neurosci Lett 228:17-20.
20. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, and Ihara Y (1994) Visualizationof A beta 42(43) and A beta 40 in senile plaques with end-specific A betamonoclonals: evidence that an initially deposited species is A beta 42(43). Neuron13:45-53.
21. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, CopelandNG, Lee MK, Younkin LH, and Wagner SL, et al. (2004) Mutant presenilinsspecifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidencefor augmentation of a 42-specific gamma secretase. Hum Mol Genet 13:159-170.
22. Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, StefanssonH, Sulem P, Gudbjartsson D, and Maloney J, et al. (2012) A mutation in APPprotects against Alzheimer's disease and age-related cognitive decline. Nature488:96-99.
23. Kounnas MZ, Danks AM, Cheng S, Tyree C, Ackerman E, Zhang X, Ahn K, NguyenP, Comer D, and Mao L, et al. (2010) Modulation of gamma-secretase reduces betaamyloiddeposition in a transgenic mouse model of Alzheimer's disease. Neuron 67:769-780.
24. Li J, Llano DA, Ellis T, LeBlond D, Bhathena A, Jhee SS, Ereshefsky L, Lenz R, and Waring JF (2012) Effect of human cerebrospinal fluid sampling frequency onamyloid-b levels. Alzheimers Dement 8:295-303.
25. Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, Cutler N, Dufour-Rainfray D, Fagan AM, and Heegaard NH, et al.; Alzheimer's AssociationQC Program Work Group (2013) CSF biomarker variability in the Alzheimer'sAssociation quality control program. Alzheimers Dement 9:251-261.
26. Mitani Y, Yarimizu J, Saita K, Uchino H, Akashiba H, Shitaka Y, Ni K, and Matsuoka N (2012) Differential effects between γ-secretase inhibitors andmodulators on cognitive function in amyloid precursor protein-transgenic andnontransgenic mice. J Neurosci 32:2037-2050.
27. Moonis M, Swearer JM, Dayaw MP, St George-Hyslop P, Rogaeva E, Kawarai T, and Pollen DA (2005) Familial Alzheimer disease: decreases in CSF Abeta42 levelsprecede cognitive decline. Neurology 65:323-325.
28. Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, Holtzman DM, and Mintun MA(2010) APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitivelynormal aging. Ann Neurol 67:122-131.
29. Okochi M, Tagami S, and Takeda M (2010) Analysis of APL1beta28, a surrogatemarker for Alzheimer Abeta42, indicates altered precision of gamma-cleavage inthe brains of Alzheimer disease patients. Neurodegener Dis 7:42-45.
30. Olsauskas-Kuprys R, Zlobin A, and Osipo C (2013) Gamma secretase inhibitors ofNotch signaling. Onco Targets Ther 6:943-955.
31. Pettersson M, Stepan AF, Kauffman GW, and Johnson DS (2013) Novel γ-secretasemodulators for the treatment of Alzheimer's disease: a review focusing on patentsfrom 2010 to 2012. Expert Opin Ther Pat 23:1349-1366.
32. Pica-Mendez AM, Tanen M, Dallob A, Tanaka W, and Laterza OF (2010) Nonspecificbinding of Aβ42 to polypropylene tubes and the effect of Tween-20. Clin Chim Acta411:1833.
33. Potter R, Patterson BW, Elbert DL, Ovod V, Kasten T, Sigurdson W, Mawuenyega K, Blazey T, Goate A, and Chott R, et al. (2013) Increased in vivo amyloid-b42 production, exchange, and loss in presenilin mutation carriers. Sci Transl Med 5:189ra77.
34. Qi-Takahara Y, Morishima-Kawashima M, Tanimura Y, Dolios G, Hirotani N, Horikoshi Y, Kametani F, Maeda M, Saido TC, and Wang R, et al. (2005) Longerforms of amyloid beta protein: implications for the mechanism of intramembranecleavage by gamma-secretase. J Neurosci 25:436-445.
35. Ringman JM, Younkin SG, Pratico D, Seltzer W, Cole GM, Geschwind DH, Rodriguez-Agudelo Y, Schaffer B, Fein J, and Sokolow S, et al. (2008) Biochemicalmarkers in persons with preclinical familial Alzheimer disease. Neurology 71:85-92.
36. Takami M, Nagashima Y, Sano Y, Ishihara S, Morishima-Kawashima M, FunamotoS, and Ihara Y (2009) gamma-Secretase: successive tripeptide and tetrapeptiderelease from the transmembrane domain of beta-carboxyl terminal fragment. J Neurosci 29:13042-13052.
37. Tamayev R and D'Adamio L (2012) Inhibition of γ-secretase worsens memory deficitsin a genetically congruous mouse model of Danish dementia. Mol Neurodegener 7:19.
38. Tate B, McKee TD, Loureiro RM, Dumin JA, Xia W, Pojasek K, Austin WF, FullerNO, Hubbs JL, and Shen R, et al. (2012) Modulation of gamma-secretase for thetreatment of Alzheimer's disease. Int J Alzheimers Dis 2012:210756.
39. Teunissen CE, Petzold A, Bennett JL, Berven FS, Brundin L, Comabella M, Franciotta D, Frederiksen JL, Fleming JO, and Furlan R, et al. (2009) A consensusprotocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 73:1914-1922.
40. Toyn J (2015) What lessons can be learned from failed Alzheimer's disease trials?Expert Rev Clin Pharmacol 8:267-269.
41. Toyn JH and Ahlijanian MK (2014) Interpreting Alzheimer's disease clinical trials inlight of the effects on amyloid-b. Alzheimers Res Ther 6:14.
42. Toyn JH, Raybon J, Meredith JE, Robertson AS, Guss V, Hoque N, Sweeney F, ZhuoX, Clarke W, and Snow K, et al. (2016) Robust translation of GSM pharmacologyacross preclinical species and human subjects. J Pharmacol Exp Ther 358:125-137.
43. Vanderstichele H, Bibl M, Engelborghs S, Le Bastard N, Lewczuk P, Molinuevo JL, Parnetti L, Perret-Liaudet A, Shaw LM, and Teunissen C, et al. (2012) Standardizationof preanalytical aspects of cerebrospinal fluid biomarker testing forAlzheimer's disease diagnosis: a consensus paper from the Alzheimer's BiomarkersStandardization Initiative. Alzheimers Dement 8:65-73.
44. Wan Z, Hall A, Jin Y, Xiang JN, Yang E, Eatherton A, Smith B, Yang G, Yu H, and Wang J, et al. (2011a) Pyridazine-derived γ-secretase modulators. Bioorg MedChem Lett 21:4016-4019.
45. Wan Z, Hall A, Sang Y, Xiang JN, Yang E, Smith B, Harrison DC, Yang G, Yu H, and Price HS, et al. (2011b) Pyridine-derived γ-secretase modulators. Bioorg MedChem Lett 21:4832-4835.
46. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, Findlay KA, Smith TE, Murphy MP, and Bulter T, et al. (2001) A subset of NSAIDs lower amyloidogenicAbeta42 independently of cyclooxygenase activity. Nature 414:212-216.
47. Yanagida K, Okochi M, Tagami S, Nakayama T, Kodama TS, Nishitomi K, Jiang J, Mori K, Tatsumi S, and Arai T, et al. (2009) The 28-amino acid form of an APLP1-derived Abeta-like peptide is a surrogate marker for Abeta42 production in the central nervous system. EMBO Mol Med 1:223-235.